Copyright
©The Author(s) 2021.
World J Clin Oncol. Feb 24, 2021; 12(2): 103-114
Published online Feb 24, 2021. doi: 10.5306/wjco.v12.i2.103
Published online Feb 24, 2021. doi: 10.5306/wjco.v12.i2.103
Table 3 Patient characteristics
| irAE | ||||||||||
| Overall | Yes | No | P value | |||||||
| n | Median | (Q1, Q3) | n | Median | (Q1, Q3) | n | Median | (Q1, Q3) | ||
| Number of cycles of immunotherapy | 277 | 5 | (2, 12) | 82 | 8.0 | (3.0, 19.0) | 195 | 4.0 | (2.0, 9.0) | 0.0011 |
| LDH | 55 | 243 | (171, 290) | 25 | 190 | (163, 259) | 30 | 253 | (186, 383) | 0.0376 |
| Progression free survival (mo) | 118 | 3.9 | (1.9, 7.4) | 27 | 5.8 | (2.7, 13.0) | 91 | 3.0 | (1.7, 6.8) | 0.0204 |
| Overall survival (mo) | 288 | 11.5 | (2.9, 19.4) | 89 | 17.1 | (8.4, 23.5) | 199 | 7.2 | (2.1, 15.3) | < 0.0001 |
- Citation: Peravali M, Gomes-Lima C, Tefera E, Baker M, Sherchan M, Farid S, Burman K, Constantinescu F, Veytsman I. Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responses. World J Clin Oncol 2021; 12(2): 103-114
- URL: https://www.wjgnet.com/2218-4333/full/v12/i2/103.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i2.103